Baird

Best 1) Caliper Life Sciences (NASDAQ: CALP): Shares of Caliper Life Sciences are currently trading up 41% from yesterday's close to $10.41. The company will be acquired by PerkinElmer (NYSE: PKI) for $10.50 per share. The deal is valued at $600 million. 2) Achillion Pharmaceuticals (NASDAQ:...

Baird is downgrading Cushing MLP (NYSE: SRV) from Outperform to Neutral.

Is this the internal document all Verizon (NYSE: VZ) cell phone subscribers have been waiting for? According to the release, an "iconic device" will begin shipping November 9. It's not like Apple Inc. (NASDAQ: AAPL) to not announce its products at least a few weeks beforehand, and the iPhone...

Baird this morning upgraded Bucyrus International (NASDAQ: BUCY) to Outperform from Neutral and maintained their $83 target. The firm is basing their upgrade on underperformance over the past four weeks and a relatively more favorable view of the Terex Mining acquisition after touring Bucyrus'...

Analysts Steven M. Ashley and Joel R. Hamann at Baird have released an update on Citrix Systems, Inc. (NASDAQ: CTXS). The company reported its first-quarter results on Wednesday. Citrix reported first-quarter EPS of $0.40, which was in-line with consensus estimate of $0.40 and slightly ahead of...

Analysts Reik W. Read and Dan J. McIntosh at Baird have released an update on Plexus Corp. (NASDAQ: PLXS). Plexus reported its first-quarter results on Wednesday. The company reported first-quarter revenue of $491 million, which was in-line with analysts’ estimate. EPS came in at $0.51, beating...

Analysts Whit Mayo and Matthew Gillmor at Baird have released an update on Addus HomeCare Corp. (NASDAQ: ADUS). Analysts believe that the state of disarray within Illinois is currently at its peak, but not getting better. According to analysts, on the positive side, the state has a new internal...

Baird analysts Whit Mayo and Matthew Gillmor reiterated their Outperform rating for shares of Universal Health Services, Inc. (NYSE: UHS) and raised their price target from $40 to $41. The Baird analysts said that guidance was positive and commented that, "adjusted for $0.18 in lost earnings from...

Analysts at Baird have maintained an Outperform rating for Brady Corporation (NYSE: BRC). The price target for the Brady Corporation has also been maintained at $37. The company reported EPS of $0.33 in the second-quarter, which came in line with consensus. The stronger-than-expected results in...

Analysts at Baird have released an update on Bucyrus International, Inc. (NASDAQ: BUCY). The company expects revenue to be in the range of $2.65-$2.75 billion in 2010, which is ahead of the consensus of $2.49 billion. The company forecasts EBITDA to remain flat or decline by up to 4%. This decline...